BrainsWay Posts Strong Q2 2026 Growth with 35% Revenue Surge
Event summary
- Q2 2026 revenue increased 35% year-over-year to $17.1 million.
- Adjusted EBITDA more than doubled to $3.5 million, with margin expanding to 20%.
- Shipped a record 125 Deep TMS systems in Q2 2026, a 42% increase year-over-year.
- Remaining performance obligations (RPOs) grew 30% year-over-year to $80.4 million.
- Updated FY 2026 revenue guidance to $68–70 million, up from previous range of $66–68 million.
The big picture
BrainsWay's strong Q2 2026 results reflect growing demand for non-invasive neurostimulation treatments, particularly in mental health. The company's ability to double its adjusted EBITDA margin while increasing system shipments highlights operational efficiency and market traction. As the industry shifts towards more advanced and targeted therapies, BrainsWay's strategic investments in minority portfolios like Hopemark Health and Radial Health position it for long-term growth.
What we're watching
- Revenue Growth Sustainability
- Whether BrainsWay can maintain its 35% revenue growth pace into Q3 and beyond, given the competitive landscape in neurostimulation.
- Operational Efficiency
- How the company will leverage its expanding EBITDA margin to fund further innovation and market expansion.
- Market Expansion
- The pace at which BrainsWay can expand insurer coverage for its SWIFT protocol, driving higher utilization of its installed base.
Related topics